{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:54:13Z","timestamp":1790848453343,"version":"4.1.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer is one of the most commonly diagnosed malignancies among women worldwide and is frequently curable when identified at an early stage. However, advanced and metastatic disease continue to account for a substantial proportion of breast cancer-related deaths, particularly among patients with aggressive subtypes such as inflammatory breast cancer (IBC), a clinicopathologic entity that spans hormone receptor-positive, HER2-positive, and triple-negative disease. Although advances in molecular profiling and systemic therapies have improved outcomes, substantial challenges persist in identifying patients at risk for recurrence, accurately assessing treatment response, and determining optimal therapeutic strategies. These challenges are driven by marked tumor heterogeneity and the dynamic interplay between malignant cells and their surrounding tumor microenvironment (TME). This review examines key barriers to the diagnosis and management of IBC, set against the broader landscape of advanced breast cancer. It discusses the clinical significance of late metastatic relapse, rapidly progressive disease, shortcomings of current prognostic frameworks, and the difficulties associated with monitoring metastatic involvement. Also highlighted are emerging approaches, including circulating tumor DNA (ctDNA) and other liquid biopsy technologies, that may enhance risk stratification, longitudinal surveillance, and detection of molecular resistance; these applications remain investigational, and established clinical approaches are distinguished from emerging strategies throughout. The TME is further explored as a critical determinant of tumor behavior, with emphasis on lymphoid and myeloid immune cells, stromal components, and immune checkpoint pathways that promote immune evasion and therapeutic resistance. Finally, this review surveys evolving treatment paradigms, including immunotherapeutic approaches, RNA-based diagnostics and therapeutics, most of which remain preclinical, and antibody-drug conjugates, which are expanding the therapeutic landscape for advanced disease. Together, these developments underscore the potential of integrating molecular, immunologic, and circulating biomarker data to enable more precise disease characterization and treatment selection, as essential for developing more effective, personalized strategies for patients with IBC and other advanced breast cancers.<\/jats:p>","DOI":"10.3389\/fonc.2026.1935087","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:56:14Z","timestamp":1790844974000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammatory breast cancer among advanced breast malignancies: diagnostic, microenvironmental, and therapeutic challenges of the rare amongst the common"],"prefix":"10.3389","volume":"16","author":[{"given":"Shayla","family":"Murray","sequence":"first","affiliation":[{"name":"Department of Medicine, Drexel University College of Medicine","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville","place":["Greenville, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30192-4","article-title":"Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system","volume":"18","author":"Fouad","year":"2017","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0010-y","article-title":"Inflammatory breast cancer biology: the tumour microenvironment is key","volume":"18","author":"Lim","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS17-OT1-02-01","article-title":"Abstract OT1-02-01: A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (MIBC) or non-IBC triple negative breast cancer (non-IBC TNBC) who have achieved clinical response or stable disease to prior chemotherapy","volume":"78","author":"Willey","year":"2018","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05571-z","article-title":"Inflammatory breast cancer cells are characterized by abrogated TGF\u03b21-dependent cell motility and SMAD3 activity","volume":"180","author":"Rypens","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.4258","article-title":"Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5","volume":"36","author":"Dowsett","year":"2018","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer (SWOG S1007, RxPONDER)","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P1-01-28","article-title":"Abstract P1-01-28: Molecular residual disease precedes radiographic confirmation of recurrence in patients with stage III inflammatory breast cancer","volume":"31","author":"Chen","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00908","article-title":"Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer","volume":"40","author":"Lipsyc-Sharf","year":"2022","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(26)00287-1","article-title":"Camizestrant versus continued aromatase inhibitor therapy after emergence of ESR1 mutation in circulating tumor DNA (SERENA-6)","volume":"27","author":"Turner","year":"2026","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: circulating tumour DNA analysis to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41698-024-00729-0","article-title":"Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/bcr309","article-title":"The E-cadherin\/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression","volume":"3","author":"Berx","year":"2001","journal-title":"Breast Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4015","article-title":"Precision medicine for cancer with next-generation functional diagnostics","volume":"15","author":"Friedman","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00277","article-title":"Dynamics of long-term patient-reported quality of life and health behaviors after adjuvant breast cancer chemotherapy","volume":"40","author":"Di Meglio","year":"2022","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.09.006","article-title":"Circulating biomarkers in breast cancer","volume":"22","author":"Seale","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061377","article-title":"Breast cancer with bone metastasis: Molecular insights and clinical management","volume":"10","author":"Venetis","year":"2021","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.772530","article-title":"Bone metastases are measurable: The role of whole-body MRI and positron emission tomography","volume":"11","author":"Oprea-Lager","year":"2021","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1643179","article-title":"Determination and clinical features of bone pseudoprogression in metastatic breast cancer","volume":"15","author":"Xu","year":"2025","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.059832","article-title":"Serum tumor markers in breast cancer: Are they of clinical value","volume":"52","author":"Duffy","year":"2006","journal-title":"Clin Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07066-z","article-title":"Diagnostic value of alkaline phosphatase and bone-specific alkaline phosphatase for metastases in breast cancer: a systematic review and meta-analysis","volume":"202","author":"Jiang","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-443-29279-8.00010-7","article-title":"Prognostic biomarkers: predicting disease outcomes","volume-title":"The Potential of Cancer Biomarkers","author":"Sah","year":"2025"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0043-5","article-title":"Circulating tumor DNA and liquid biopsy in oncology","volume":"1","author":"Cescon","year":"2020","journal-title":"Nat Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: Functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJM200007063430107","article-title":"The immune system: first of two parts","volume":"343","author":"Delves","year":"2000","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12941","article-title":"The opposing roles of CD4+ T cells in anti-tumour immunity","volume":"154","author":"Ahrends","year":"2018","journal-title":"Immunology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13058-020-01371-x","article-title":"Immune phenotype of patients with stage IV metastatic inflammatory breast cancer","volume":"22","author":"Fernandez","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217550","article-title":"The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4+ T cell polarization in inflammatory and non-inflammatory breast cancer patients","volume":"14","author":"Saleh","year":"2019","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1929724","article-title":"Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors","volume":"10","author":"Bertucci","year":"2021","journal-title":"Oncoimmunology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13058-019-1108-1","article-title":"Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression","volume":"21","author":"Van Berckelaer","year":"2019","journal-title":"Breast Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132710","article-title":"Inflammation mediated metastasis: Immune induced epithelial-to-mesenchymal transition in inflammatory breast cancer cells","volume":"10","author":"Cohen","year":"2015","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9427","DOI":"10.1038\/s41598-018-27409-x","article-title":"CSF-1\/CSF-1R axis is associated with epithelial\/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer","volume":"8","author":"Kai","year":"2018","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12935-024-03525-9","article-title":"Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies","volume":"24","author":"Taghizadeh Anvar","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2017.08.109","article-title":"Role of interleukin (IL)-17 and T-helper (Th)17 cells in cancer","volume":"493","author":"Song","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.129641","article-title":"Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer","volume":"5","author":"Garaud","year":"2019","journal-title":"JCI Insight"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1481","article-title":"Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer","volume":"24","author":"Wouters","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4834-7","article-title":"The combined presence of CD20+ B cells and PD-L1+ tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome","volume":"171","author":"Arias-Pulido","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B46","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12935-021-02004-9","article-title":"Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis","volume":"21","author":"Qin","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2158","article-title":"Inflammatory breast cancer promotes development of M2 tumor-associated macrophages and cancer mesenchymal cells through a complex chemokine network","volume":"79","author":"Valeta-Magara","year":"2019","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194883","article-title":"Influence of macrophages on vascular invasion of inflammatory breast cancer emboli measured using an in vitro microfluidic multi-cellular platform","volume":"15","author":"Gadde","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-018-0769-1","article-title":"Targeting Gas6\/TAM in cancer cells and tumor microenvironment","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13058-025-02015-8","article-title":"AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization","volume":"27","author":"Phi","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12694","article-title":"Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models","volume":"7","author":"Wolfe","year":"2016","journal-title":"Oncotarget"},{"key":"B52","unstructured":"A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)\n          \n          2017"},{"key":"B53","unstructured":"A Phase Ib\/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-Panbc)\n          \n          2018"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-\u03b2: \u201cN1\u201d versus \u201cN2\u201d TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01146","article-title":"Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy","volume":"9","author":"Masucci","year":"2019","journal-title":"Front Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.22034\/APJCP.2017.18.10.2689","article-title":"Tumor-associated neutrophils in breast cancer subtypes","volume":"18","author":"Soto-Perez-de-Celis","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61067","article-title":"Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis","volume":"122","author":"Jamieson","year":"2012","journal-title":"J Clin Invest"},{"key":"B59","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","article-title":"Neutrophils in cancer carcinogenesis and metastasis","volume":"14","author":"Xiong","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112584","article-title":"Pivotal role for Cxcr2 in regulating tumor-associated neutrophil in breast cancer","volume":"13","author":"Timaxian","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.7150\/jca.23969","article-title":"International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference","volume":"9","author":"Ueno","year":"2018","journal-title":"J Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3965","article-title":"Towards a molecular understanding of microRNA-mediated gene silencing","volume":"16","author":"Jonas","year":"2015","journal-title":"Nat Rev Genet"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2015.07.011","article-title":"The functions of microRNAs: mRNA decay and translational repression","volume":"25","author":"Iwakawa","year":"2015","journal-title":"Trends Cell Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz097","article-title":"An estimate of the total number of true human miRNAs","volume":"47","author":"Alles","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1783","article-title":"MicroRNA gene expression deregulation in human breast cancer","volume":"65","author":"Iorio","year":"2005","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1261\/rna.1034808","article-title":"MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis","volume":"14","author":"Yan","year":"2008","journal-title":"RNA"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118647","article-title":"Prediction of poor prognosis in breast cancer patients based on microRNA-21 expression: a meta-analysis","volume":"10","author":"Wang","year":"2015","journal-title":"PloS One"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2416","article-title":"The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells","volume":"67","author":"Mertens-Talcott","year":"2007","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.09.007","article-title":"Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA","volume":"363","author":"Liang","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"B72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drup.2013.05.001","article-title":"MicroRNAs as therapeutic targets in chemoresistance","volume":"16","author":"Garofalo","year":"2013","journal-title":"Drug Resist Update"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.01278","article-title":"Targeted inhibition of miR-221\/222 promotes cell sensitivity to cisplatin in triple-negative breast cancer MDA-MB-231 cells","volume":"10","author":"Li","year":"2020","journal-title":"Front Genet"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7791","article-title":"Lipid based nanoparticles for the therapeutic delivery of non coding RNAs in breast cancer (review)","volume":"44","author":"Silva-C\u00e1zares","year":"2020","journal-title":"Oncol Rep"},{"key":"B75","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ijpharm.2017.07.079","article-title":"Enhanced efficacy of anti-miR-191 delivery through stearylamine liposome formulation for the treatment of breast cancer cells","volume":"530","author":"Sharma","year":"2017","journal-title":"Int J Pharm"},{"key":"B76","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41523-025-00800-4","article-title":"Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions","volume":"11","author":"Patel","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40164-025-00632-9","article-title":"Antibody-drug conjugates in breast cancer: current evidence and future directions","volume":"14","author":"Li","year":"2025","journal-title":"Exp Hematol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1935087\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:56:18Z","timestamp":1790844978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1935087\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":77,"alternative-id":["10.3389\/fonc.2026.1935087"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1935087","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1935087"}}